Our Mission: To be the International Leader in Providing New Therapies for Treatment and Prevention of Vascular Dementia and Inflammation Related Memory Loss.

ProNeurogen’s drug candidates offer first in class treatments for the treatment and prevention of inflammation-related brain disorders. This includes cognitive impairment and memory loss associated with vascular dementia, post-operative cognitive decline, pre-Alzheimer’s, heart failure and cardiovascular disease. To date, there are no FDA-approved drugs specifically to treat cognitive impairment and memory loss caused by brain inflammation.

The ProNeurogen Team includes internationally-recognized experts in peptide biology and glycoengineering, neurology, memory impairment and cognitive dysfunction.

ProNeurogen was founded in 2013 to commercialize a therapeutic based on research and associated intellectual property developed at the University of Arizona.